YijiaDa Completes Tens of Millions RMB Pre-A Financing to Advance Innovative Solutions in Urology and Pelvic Floor Health

VCBeat (WeChat ID: vcbeat) has learned that Better MedTech (Shanghai) Co., Ltd. (“Better MedTech”) has completed a Pre-A financing round worth tens of millions of yuan. The round was led by Chende Capital, with participation from Longma Peak Venture Capital and existing investor Huachuang Capital. Puwan Capital served as the financial advisor. Previously, Better MedTech secured exclusive investment from Huachuang Capital in its angel round.

This round of financing will be used to support Better MedTech in the continuous innovation, clinical studies, commercialization, and establishment of R&D and production centers for its urology and pelvic floor health products.

Since its inception in 2021, Better MedTech has positioned itself as a provider of innovative solutions focused on urological and pelvic floor health. The company has implemented a comprehensive and precise portfolio of innovative products in blue-ocean markets such as benign prostatic hyperplasia, urinary incontinence, stone disease, and novel oncology therapies, with the aim of establishing itself as a leading brand in the urology sector.

The urology and pelvic floor health sector has long been an underestimated market, yet it is experiencing rapid growth. In terms of major disease categories, approximately 6% of adults in China suffer from kidney stones, over 50% of men aged 50 and above are affected by benign prostatic hyperplasia (BPH), and more than 20% of women experience varying degrees of urinary incontinence. The urology market in China remains a blue ocean: on one hand, there is a scarcity of innovative, high-quality products; on the other, the urological device industry is fragmented and lacks brands with comprehensive strategic layouts.

Mr. Zhu Yichen, Founder and CEO of Better MedTech, stated: “Better MedTech does not position itself as a company focused on single-product R&D; rather, we aim to become a category-leading and platform-based enterprise. Our team brings together elites from top multinational corporations (MNCs) both domestically and internationally, spanning multiple functions including marketing, R&D, and clinical affairs in the urology field. Through independent innovation, medical-engineering collaboration, and industrial partnerships, we have rapidly established comprehensive product portfolios across major disease areas, thereby facilitating more effective commercialization and brand building.”

Many urological and pelvic floor disorders are chronic, progressive conditions characterized by high recurrence rates, difficulty in achieving a complete cure with a single surgical intervention, numerous surgical complications, and a lack of appropriate treatment options for a significant proportion of advanced-stage cases. Taking benign prostatic hyperplasia (BPH) as an example, small-to-medium-sized glands are often managed solely with medication, whereas traditional treatments such as electrocautery or laser therapy for medium-to-large glands are associated with higher complication rates. In light of these challenges, Better MedTech has designed and developed comprehensive, systematic solutions—including suspension systems and magnetically controlled sphincters—through innovative product portfolios tailored to patients with varying gland sizes, clinical conditions, and ages.

Mr. He Mingchen, Co-founder and CTO of Better MedTech, stated, “The era of relying on a single product to dominate the market is over. We firmly believe in a comprehensive and precise, patient-needs-oriented approach to our full product portfolio. By accelerating product development and time-to-market, we aim to deliver better treatment solutions to more patients.”

Chende Capital's investment team stated:The Better MedTech team has cultivated deep expertise in the urology field for many years, combining keen market insight with professional experience in medical device R&D, marketing, and platform-based operations. We aim to bring our products to market at the earliest opportunity, thereby benefiting the large population of patients with urological and pelvic floor conditions who currently lack access to effective treatment.

Mr. Lu Hanjie, Partner at Huachuang, stated:We are optimistic about innovation in the field of urology and pelvic floor health. Driven by major trends such as population aging, the shift toward outpatient care, and the decentralization of diagnosis and treatment to home settings, this market holds substantial untapped opportunities. Better MedTech is well-positioned to become a pioneer and leader in urology and pelvic floor health.

Mr. Yu Tiandong, Partner at Longma Peak Ventures, stated:Better MedTech has demonstrated impressive execution capabilities and progress since its inception. We fully recognize the past achievements of the team led by Mr. Zhu and Mr. He, and we eagerly anticipate the future potential of its products. We look forward to witnessing Better MedTech’s grand expansion and rapid growth in the urology field.